INSMED
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chroni... c infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
INSMED
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1988-01-01
Address:
Bridgewater, New Jersey, United States
Country:
United States
Website Url:
http://www.insmed.com
Total Employee:
501+
Status:
Active
Contact:
+1 732) 997-4600
Email Addresses:
[email protected]
Total Funding:
1.37 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-12-02 | Transave | Transave acquired by Insmed | N/A |
| 2000-05-31 | Celtrix Pharmaceuticals | Celtrix Pharmaceuticals acquired by Insmed | N/A |
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Post-IPO Equity - Insmed
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-23 | Insmed Names Drayton Wise Chief Commercial Officer |
| 2020-01-30 | Insmed appoints Bonstein chief financial officer |
Official Site Inspections
http://www.insmed.com Semrush global rank: 2.3 M Semrush visits lastest month: 8.16 K
- Host name: 195.126.196.104.bc.googleusercontent.com
- IP address: 104.196.126.195
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Insmed"
About Insmed - Learn About Our Values, Mission, and Team
An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future. From the early days of the two original companies that formed Insmed to the FDA …See details»
Contact Us - Insmed
Discovery Dialogues at Insmed. Sit down with members of Insmed’s global Research team as they discuss our approach to developing life-transforming medicines while tackling some of the most pressing scientific challenges …See details»
Business - Insmed
Developed in Insmed’s laboratories and commercialized by our team across these three regions, it is the cornerstone of our global business. It is also the only product strongly recommended in international guidelines for the treatment of …See details»
Purpose - Insmed
Culture. Nearly 1,000 employees around the globe; No. 1 Science Top Employer for third year in a row; U.S. Great Place to Work Certification for third year in a row; No. 1 on 2023 Best …See details»
Culture - annualreport.insmed.com
Hosted 6 Insmed Cares volunteer events and 13 charitable team building activities; Collected 4,000+ in-kind donations; ... With this opportunity in mind, I am looking forward to providing …See details»
Investor Relations | Insmed Incorporated
6 days ago Insmed (Nasdaq:INSM) is a people-first global biopharmaceutical company on a mission to transform the lives of patients facing serious and rare diseases. Our strong and experienced management team embodies our …See details»
Insmed - Crunchbase Company Profile & Funding
Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled …See details»
Insmed Incorporated Investor Relations - Annual Reports
Discovery Dialogues at Insmed. Sit down with members of Insmed’s global Research team as they discuss our approach to developing life-transforming medicines while tackling some of the most pressing scientific challenges …See details»
Insmed Unites Across Communities Around the World During …
Oct 23, 2024 Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., …See details»
Insmed – 2023 Annual Report
Shareholders may receive without charge a copy of our Annual Report on Form 10-K for the year ended December 31, 2023, by going to investor.insmed.com or by sending a written request to Mr. Michael A. Smith, Corporate Secretary, …See details»
Our Responsibility - Insmed
Discovery Dialogues at Insmed. ... Our priority topics align with our organization’s continued growth and development and reaffirm our commitment to our patients and our people. These …See details»
Insmed Company Profile, Stock Price, News, Rankings - Fortune
As Insmed's business needs have changed and the organization has evolved, I have been given many, many opportunities to learn and grow with the company. Insmed values not only its …See details»
Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN …
Mar 31, 2023 Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial …See details»
Our Purpose - annualreport.insmed.com
Carol first sensed that something was wrong when she noticed a constant need to clear her throat. She mentioned it during her annual physical in early 2014, and her doctor ordered a …See details»
Insmed Reports Inducement Grants Under NASDAQ Listing Rule …
1 day ago Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients …See details»
Our Culture - Insmed
At Insmed, we believe that every moment and every patient counts. That’s why no matter the obstacles we face, we will find a way or create one to make the greatest possible impact. …See details»
Insmed (INSM) Earnings Date and Reports 2025 - MarketBeat
2 days ago Insmed posted Q3 2024 earnings on October 31, 2024, reporting an EPS of -$1.27, which missed analysts' consensus estimates of -$1.19 by $0.08. Quarterly revenue rose …See details»
Our Mission and Vision - Insmed
Discovery Dialogues at Insmed. Sit down with members of Insmed’s global Research team as they discuss our approach to developing life-transforming medicines while tackling some of the …See details»
Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers …
Oct 26, 2023 -- Insmed Leads Science Top Employers List for Third Consecutive Year -- . BRIDGEWATER, N.J., Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a …See details»
Career Opportunities and Job Listings at Insmed
In 2024, Insmed held its third annual Global Day of Good, a company-wide day of service focused on making an impact in the communities where we live and work. Over the course of the day, …See details»